financetom
Business
financetom
/
Business
/
Market Chatter: Walt Disney, Reliance Face India Antitrust Scrutiny Over Cricket
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Market Chatter: Walt Disney, Reliance Face India Antitrust Scrutiny Over Cricket
Aug 20, 2024 5:32 AM

08:05 AM EDT, 08/20/2024 (MT Newswires) -- India's antitrust watchdog has concluded preliminarily that the $8.5 billion merger of Walt Disney's ( DIS ) India assets and Reliance MediaWorks hurts competition, Reuters reported Tuesday, citing unnamed sources.

The Competition Commission of India considers the two companies' potential domination of cricket broadcast rights the main obstacle, the report said.

The watchdog has asked the companies to explain why the merger should not come under investigation, the report said.

The companies have suggested they could sell some of their television stations to ease competition concerns, but declined to budge on cricket, citing licensing agreements that do not expire until 2027 and 2028, the report said.

Disney's ( DIS ) India unit and Reliance did not immediately reply to MT Newswires' request for comment.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Price: 90.92, Change: +0.10, Percent Change: +0.11

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Takeda Wins European Commission's Approval for Adzynma to Treat Blood Clotting Disorder
Takeda Wins European Commission's Approval for Adzynma to Treat Blood Clotting Disorder
Aug 7, 2024
11:45 AM EDT, 08/07/2024 (MT Newswires) -- Takeda Pharmaceutical ( TAK ) said Wednesday it received approval from the European Commission for Adzynma for the treatment of congenital thrombotic thrombocytopenic purpura, a rare blood clotting disorder caused by a deficiency in the ADAMTS13 enzyme. Takeda said the EC approval does not have any impact on its consolidated forecast for the...
Update: KITS Eyecare Up 3.4% as It Swings to Q2 Profit as Revenue Hits a Record High
Update: KITS Eyecare Up 3.4% as It Swings to Q2 Profit as Revenue Hits a Record High
Aug 7, 2024
11:45 AM EDT, 08/07/2024 (MT Newswires) -- KITS Eyecare ( KTYCF ) on Wednesday said it swung to a profit in the second-quarter as revenue jumped 26% to a record. The on-line eyeglasses company said its second-quarter came in at $187,000, or $0.01 per share, swinging from a loss of $1.2 million, or $0.04, in the year-prior period. Revenue rose...
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks
Aug 7, 2024
On Tuesday, Emergent BioSolutions Inc. ( EBS ) reported second-quarter 2024 sales of $254.7 million, down 25% year over year, beating the consensus of $190 million. The company reported an adjusted EPS loss of $(2.32), more than double the $(1.05) reported a year ago, missing the consensus of $(0.94). Revenues from Narcan (naloxone HCl) Nasal Spray decreased 10% to $120 million, primarily...
Update: ShaMaran Closes Transaction to Increase Its Working Interest in the Atrush Block in Iraq's Kurdistan Region
Update: ShaMaran Closes Transaction to Increase Its Working Interest in the Atrush Block in Iraq's Kurdistan Region
Aug 7, 2024
11:49 AM EDT, 08/07/2024 (MT Newswires) -- ShaMaran Petroleum ( SHASF ) on Wednesday said it closed the acquisition of TAQA Atrush and the subsequent sale of an indirect interest in Atrush to HKN Energy IV. The two-step transaction announced in January increased ShaMaran's 28% indirect stake in the Atrush oil block in Iraq's Kurdistan region to a 50% working...
Copyright 2023-2025 - www.financetom.com All Rights Reserved